Subject(s)
Myocardial Infarction/drug therapy , Peptides/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Angioplasty , Chi-Square Distribution , Coronary Circulation/drug effects , Emergency Service, Hospital , Eptifibatide , Female , Humans , Male , Middle Aged , Myocardial Infarction/therapy , Myocardial Reperfusion , Treatment OutcomeSubject(s)
Folic Acid Deficiency/epidemiology , Folic Acid/administration & dosage , Spinal Dysraphism/complications , Adolescent , Adult , Baltimore/epidemiology , Delaware/epidemiology , Dietary Supplements , Female , Folic Acid Deficiency/etiology , Food, Fortified , Humans , Nutritional Requirements , Prevalence , Risk Factors , Spinal Dysraphism/metabolismABSTRACT
The recommendation has been made that all women be counseled about the risks and benefits of hormone replacement therapy (HRT). Use of HRT among women undergoing coronary angiography was explored to assess whether patterns of use were similar to data drawn from community samples. Using a descriptive design, a convenience sample of 414 postmenopausal women was interviewed. Fifty-eight percent had never used HRT, 18.3% were past users, and 23.7% were currently using HRT. The primary reason given for ever using HRT was for symptoms of menopause. Less than 14% of women cited coronary heart disease (CHD) or osteoporosis as their primary reason for using HRT. The most common reasons for stopping HRT were side effects and fear of cancer. The most common reasons given for never having used HRT were that their healthcare provider had never talked about it and that they had never thought about it. Use of HRT among women undergoing coronary angiography is similar to that found in community samples. The challenge is to promote patient-provider interactions that include information about HRT based on the scientific model as well as attention to women's individual concerns.
